Exelixis, Inc.
1851 Harbor Bay Parkway
Alameda
California
94502
United States
Tel: 650-837-7000
Website: http://www.exelixis.com/
About Exelixis, Inc.
Every Exelixis employee is united in an ambitious cause: to launch innovative medicines that give patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. After operating in the challenging biotech sector for 25 years, we have a proven track record of resiliency in the face of adversity. The success of our lead product has provided a solid commercial foundation allowing us to reinvigorate our research efforts, and grow our team in areas such as Drug Discovery, Clinical Development and Commercial.
As we expand our global partnerships and further reinvest in R&D to help us discover the next breakthrough for difficult-to-treat cancers, we're seeking to add talented, dedicated employees to power our mission.
Cancer is our cause. Make it yours, too.
Stock Symbol: EXEL
678 articles with Exelixis, Inc.
-
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
9/19/2020
Opdivo in combination with CABOMETYX showed superior overall survival and doubled median progression-free survival and objective response rate with a favorable safety profile vs. sunitinib
-
Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020
9/14/2020
Exelixis, Inc. (Nasdaq: EXEL) today announced it will host an investor briefing to discuss data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The online-only event will be held following the closing of the Congress’ sessions on Saturday, September 19, 2020, beginning at 22:00 (10:00 p.m.) CEST / 4:00 p.m. EDT / 1:00
-
Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
9/8/2020
- Companies will partner to develop novel antibody-drug conjugates using NBE’s unique ADC platform - - Agreement encompasses an exclusive option on multiple targets over a two-year term, with potential to extend time and scope of the collaboration - - Deal is the fourth biologics-focused agreement for Exelixis since 2018 -
-
Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology
9/8/2020
Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag ® Bioconjugation Technology Companies will partner to develop novel antibody-drug conjugates using Catalent’s SMARTag bioconjugation platform and monoclonal antibodies from Exelixis’ growing preclinical pipeline Agreement includes exclusive options on multiple targets over three-year term, with potentia
-
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September 2020
9/8/2020
Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in September:.
-
Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX® (cabozantinib) in Combination With Opdivo® (nivolumab) for Advanced Renal Cell Carcinoma
8/24/2020
Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX ® (cabozantinib) in Combination With Opdivo ® (nivolumab) for Advanced Renal Cell Carcinoma – Submission based on the phase 3 pivotal CheckMate -9ER trial, which met its primary endpoint of significantly improving progression-free survival and secondary endpoints of overall survival and objective response rate – ALAMEDA, Calif.--( B
-
Exelixis Announces Second Quarter 2020 Financial Results and Provides Corporate Update
8/6/2020
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
-
Exelixis to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020
7/29/2020
Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 after the markets close.
-
Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma
7/20/2020
Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 pivotal trial of cabozantinib (CABOMETYX ® ) in combination with atezolizumab (TECENTRIQ ® ) in patients with inoperable, locally advanced or metastatic renal cell carcinoma (RCC) who progressed during or fo
-
Clinical Catch-Up: June 29-July 3
7/6/2020
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look. -
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer
7/2/2020
Clinical collaboration marks an important milestone in partnership with Exelixis to further develop cabozantinib
-
Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer
6/30/2020
Initiation follows positive results from cohort 6 of phase 1b COSMIC-021 trial – – CONTACT-02 is the second of three phase 3 pivotal trials that are part of a clinical collaboration with Roche – ALAMEDA, Calif.--( BUSINESS WIRE )-- Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX ® ) in combination with atezolizumab (TECENTRIQ ® ) in patients with met
-
Exelixis to Webcast Virtual Fireside Chat as Part of the BofA Securities Napa Biopharma Conference on June 24, 2020
6/18/2020
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will participate in a fireside chat as part of the virtual BofA Securities Napa Biopharma Conference on Wednesday, June 24, 2020 at 3:30 PM EDT / 12:30 PM PDT.
-
Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer
6/11/2020
Initiation follows positive results from cohort 7 of phase 1b COSMIC-021 trial – – CONTACT-01 is the first of three phase 3 pivotal trials that are part of a previously announced clinical collaboration with Roche –
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
6/3/2020
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in June:
-
Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types
5/13/2020
Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors.
-
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
5/6/2020
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in May:
-
Exelixis Announces First Quarter 2020 Financial Results and Provides Corporate Update
5/5/2020
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
-
Clinical Catch-Up: April 20-24
4/27/2020
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.